Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New Press Release - Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 23, 2023 1:24pm

124 Views

Post# 35696636

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

The global ulcerative colitis market was valued at $7.1 billion in 2020, and is projected to reach $10.8 billion by 2030. - so growth in this market segment appears to have matured, yet Roche decided to acquire Telavant for $7.1billion, presumably in part, on the strength of biomarker data in Riovants Phase2b study.

https://www.globenewswire.com/en/news-release/2023/05/08/2663523/0/en/Ulcerative-Colitis-Market-Size-Worth-USD-10-26-Billion-by-2030-at-5-20-CAGR-Report-by-Market-Research-Future-MRFR.html

Conversely, the Global pancreatic cancer market was valued at USD 2.05 billion in 2022 will expand to USD 7.40 billion by 2032.

Globally, the pancreatic cancer market is increasing due to rising cancer prevalence, change in lifestyle, for example increase in the consumption of alcohol and smoking.

The global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022

And with the potential use of pelareorep in combination with a checkpoint and CDK4/6 or PARP inhibitor, in 2L HR+/HER2- advanced or metastatic breast cancer, in which optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer is yet to be established, ONCYs acquisition valuation still remains in the multi-Billions, as witnessed today by Roches decision to acquire the experimental drug Telavant for US$7.1 Billion.

Consequently nothing has changed for ONCY in mBC other than pelareorep will be used as second line treatment in HR+/HER2- (or HER2 low) advanced or metastatic breast cancer , when combined with a CPI, on the expected treatment relapes/failures/adverse effects with the ADC Enhertu.

https://pubmed.ncbi.nlm.nih.gov/37026492/

<< Previous

Bullboard Posts

Next >>

FLYHT and WestJet partner on weather forecasting